Table 1.

Baseline clinical characteristics and biochemical measures of the entire cohort of treated patients

VariableData
Age (yr)61±9
Women 6 (40)
Type 2 diabetes11/15 (73)
Obstructive sleep apnea2/15 (13)
Pulmonary hypertension1/15 (7)
Incidentaloma1/15 (7)
Antihypertensive drugs (n)5.6±1.3
 ACEI7/15 (47)
 ARB11/15 (73)
 ACEI and ARB4/15 (27)
 β-blocker11/15 (73)
 calcium-channel blocker12/15 (80)
 α-blockers4/15 (27)
 diuretic15/15 (100)
 direct renin inhibitor4/15 (29)
 vasodilator10/14 (27)
 central acting sympatholytic7/15 (47)
Office SBP (mmHg)174±22 (154–223)
Office DBP (mmHg)91±16 (61–118)
Heart rate (beats/min)64±9 (50–75)
Creatinine estimated GFR (mL/min per 1.73 m2)31.2±8.9 (15–43)
Plasma creatinine level (µmol/L)186.7±64.4 (118–372)
  • Unless otherwise noted, data are number/number of patients (%). Values expressed with a plus/minus sign are mean ± SD; ranges in parentheses are interquartile ranges. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II–receptor blocker.